Clinical Trials Logo
  1. Home
  2. Palmoplantar Pustulosis
  3. NCT04493424

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Palmoplantar Pustulosis Clinical Trial

Official title:
An Open-label, Long Term Safety Trial of Spesolimab Treatment in Patients With Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials

Clinical Trial Summary

This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab. Participants who benefited from spesolimab treatment in the previous studies can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with palmoplantar pustulosis in the long-term. Participants are in this study for up to 5 years. During this time they visit the study site every month to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' palmoplantar pustulosis and collect information on any health problems of the participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04493424
Study type Interventional
Source Boehringer Ingelheim
Contact
Status Terminated
Phase Phase 2
Start date September 4, 2020
Completion date May 15, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05994976 - Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Completed NCT04572997 - Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) Phase 2
Completed NCT03633396 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis Phase 2
Active, not recruiting NCT05174065 - Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) Phase 3
Active, not recruiting NCT04459507 - A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
Completed NCT01780857 - Immune Signature of Palmoplantar Pustulosis N/A
Completed NCT03972280 - Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Phase 1
Completed NCT01794117 - Anakinra for Inflammatory Pustular Skin Diseases Phase 2
Recruiting NCT05710185 - Deucravacitinib for the Treatment of Palmoplantar Pustulosis Phase 4
Terminated NCT05194839 - A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) Phase 2
Active, not recruiting NCT04566471 - Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
Completed NCT03988335 - A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) Phase 2
Completed NCT02641730 - An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis Phase 3
Completed NCT04061252 - A Study of KHK4827 in Subjects With Palmoplantar Pustulosis Phase 3